Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis ; volume:8 ; number:3 ; day:4 ; month:3 ; year:2024 ; pages:445-457 ; date:5.2024
PharmacoEconomics - open ; 8, Heft 3 (4.3.2024), 445-457, 5.2024
- Urheber
-
Bührer, Christian
Paling, Thomas
Gale, Richard
Paulo, Tatiana
Bagijn, Marloes
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-023-00465-4
- URN
-
urn:nbn:de:101:1-2407112105338.369027652911
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bührer, Christian
- Paling, Thomas
- Gale, Richard
- Paulo, Tatiana
- Bagijn, Marloes
- SpringerLink (Online service)
Ähnliche Objekte (12)
Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review
Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review
Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up
Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study
Summary of Research: Cost‑Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective
Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema
Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review
Burden of Disease Study of Patients with Diabetic Macular Oedema in Spain
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial
Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
Cost of diabetic retinopathy and macular oedema in a population, an eight year follow up